Plain-English translation of NCT05970666 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a combination approach for people with advanced liver cancer that cannot be surgically removed. The treatment combines a procedure called TACE (which delivers medicine directly to the tumor) with two medications: adebrelimab and bevacizumab. The goal is to see whether this combination works better than current standard treatments.
Advanced liver cancer is difficult to treat when surgery isn't an option. Researchers believe that combining this special procedure with these two medications might be more effective at shrinking tumors and helping patients live longer.
You likely qualify if…
You likely don't qualify if…
You will receive the TACE procedure combined with intravenous infusions of the two medications as part of your treatment plan. The study involves regular clinic visits for monitoring, blood tests, and imaging scans to track how well the treatment is working. Your doctors will closely watch for any side effects and adjust your care as needed throughout the study period.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
The First Affiliated Hospital of Xiamen University
Collaborators
Jiangsu HengRui Medicine Co., Ltd.
Enrollment target
~71 participants
Started
November 2023
Primary completion
November 2026
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in February 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Jianbo Chen
The First Affiliated Hospital of Xiamen University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.